Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Candida albicans cell wall and membrane components constitute the essential outer boundaries of the fungus, providing structural integrity and regulating interactions with the host environment. The cell wall is a dynamic structure composed of an inner layer of chitin and beta-glucans (1,3-beta and 1,6-beta) and an outer layer of mannoproteins, which are critical for maintaining cell shape, resisting osmotic pressure, and facilitating adhesion to host surfaces (Gow et al., 2017, Nature Reviews Microbiology). Beneath the wall lies the plasma membrane, which contains ergosterol as its primary sterol, serving a similar role to cholesterol in mammalian cells by maintaining membrane fluidity and organizing signaling proteins (Odds et al., 2003, Journal of Antimicrobial Chemotherapy). These components are the primary targets for most clinical antifungal therapies: echinocandins inhibit the synthesis of 1,3-beta-D-glucan, while polyenes and azoles target ergosterol directly or its biosynthetic pathway, respectively (Nett & Andes, 2016, Infectious Disease Clinics of North America). Because these structures contain elements unique to fungi, they allow for selective toxicity, although the emergence of resistant strains and the potential for host toxicity, particularly with older agents like amphotericin B, remain significant therapeutic challenges (Pfaller, 2012, American Journal of Medicine).
Antifungal drugs targeting these components operate through three primary mechanisms: inhibition of 1,3-beta-D-glucan synthase to disrupt cell wall polymers (echinocandins), direct binding to ergosterol to create lethal trans-membrane pores (polyenes), and inhibition of lanosterol 14-alpha-demethylase (CYP51) to deplete ergosterol and accumulate toxic sterol intermediates (azoles) (Nett & Andes, 2016, Infectious Disease Clinics of North America; Odds et al., 2003, Journal of Antimicrobial Chemotherapy).
10 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Candida albicans cell wall and membrane components.